Mon.Jul 10, 2023

article thumbnail

European regulators probe suicide risk to Ozempic, other Novo drug Saxenda

Bio Pharma Dive

Three reports from Iceland spurred the EMA to evaluate whether certain Novo Nordisk drugs, including Ozempic, might cause thoughts of self harm.

article thumbnail

Staying Up All Night May Actually Relieve Depression in Some People

AuroBlog - Aurous Healthcare Clinical Trials blog

As most new parents can attest, sleepless nights don’t exactly make for the most cheerful mornings. This is why it makes little sense that total sleep deprivation temporarily resets the mood of nearly half of people with a major depressive disorder.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Astellas buys rights to 4D Molecular’s technology in latest gene therapy deal

Bio Pharma Dive

The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.

article thumbnail

July 10, 2023: EHR Core’s Keith Marsolo Shares Scientific Goals and Resources Needed For Data Sharing

Rethinking Clinical Trials

In an interview at the NIH Pragmatic Trials Collaboratory Steering Committee Meeting in May, Keith Marsolo, PhD, Co-Chair of the Electronic Health Records Core , reflected on data sharing experiences from the program and factors affecting the meaningful re-use of data. Keith Marsolo, PhD “The data sharing experiences from the NIH Pragmatic Trials Collaboratory Demonstration Projects have been fairly limited.

Trials 130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Overcoming AAV manufacturing challenges

Bio Pharma Dive

Overcome issues with AAV vector scalability and reproducibility. Enable a wider application of gene therapies in a cost-effective and sustainable way.

article thumbnail

ZyVersa’s cholesterol efflux mediator gains patent in Europe

Pharmaceutical Technology

ZyVersa Therapeutics has received a patent from the European Patent Office for VAR 200 to treat diabetic nephropathy/diabetic kidney disease.

130
130

More Trending

article thumbnail

IGC Pharma obtains funds to boost Alzheimer’s research

Pharmaceutical Technology

IGC Pharma has obtained a revolving line of credit worth $12m from the O-Bank’s Hong Kong branch to bolster research in Alzheimer’s disease.

Research 130
article thumbnail

Novartis to appeal district court ruling on heart drug patent

Bio Pharma Dive

The patent is an important line of defense protecting Entresto, Novartis’ current top-selling medicine, from generic competition in the U.S.

Medicine 139
article thumbnail

NS Pharma’s NS-089/NCNP-02 gains FDA rare paediatric disease status

Pharmaceutical Technology

The US FDA has awarded rare paediatric disease designation to NS Pharma’s NS-089/NCNP-02 to treat Duchenne muscular dystrophy.

130
130
article thumbnail

Nanobiotix licenses cancer treatment to J&J, extending runway

Bio Pharma Dive

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 139
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

FDA grants orphan drug status for Ichnos’ multiple myeloma antibody

Pharmaceutical Technology

The US FDA has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.

Antibody 130
article thumbnail

Quest and Proov collaborate to bring novel home fertility test to women through questhealth.com

AuroBlog - Aurous Healthcare Clinical Trials blog

Women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com.

Hormones 122
article thumbnail

Investor sentiment surges for US companies, with European and APAC firms undervalued

Pharmaceutical Technology

US pharma companies take the lead in the rankings of the top five companies based on market capitalisation and sales,

article thumbnail

Novo Nordisk's GLP-1 drugs under review in Europe after reports flag possible suicide risks

Fierce Pharma

Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbust | Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbuster products.

Drugs 123
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Novartis plans appeal to ward off Entresto generics

Pharmaceutical Technology

Despite a loss at the district court level, Novartis is projecting a positive outlook for 2023 sales for Entresto.

Sales 130
article thumbnail

Rystiggo Brings New Hope for Generalized Myasthenia Gravis Patients

XTalks

Euronext Brussels (UCB), a biopharma company headquartered in Brussels, Belgium, recently announced that the US Food and Drug Administration (FDA) has granted approval for its drug, Rystiggo (rozanolixizumab), for the treatment of generalized myasthenia gravis (gMG). UCB specializes in the discovery and development of innovative medicines for severe diseases that affect the immune system or central nervous system.

article thumbnail

Unmet needs remain in treatment of triple negative breast cancer

Pharmaceutical Technology

Despite significant need for novel therapeutics to treat triple negative breast cancer, this is proving difficult.

130
130
article thumbnail

Bang Energy’s Twist of Fate: Monster Energy as Potential Buyer

XTalks

In a twist of fate, Monster Energy may soon become both the savior and executioner of its competitor, Bang Energy. As reported by the Wall Street Journal , Monster Energy is poised to acquire its smaller rival for $362 million through a bankruptcy court agreement. This transaction is pending approval from the bankruptcy court and the Federal Trade Commission (FTC), which is currently reviewing the potential sale; however, if given the green light, this deal could potentially be beneficial for bo

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

MHRA approves GSK’s RSV vaccine for older adults in the UK

Pharmaceutical Technology

The belated decision follows RSV vaccine approvals in America and the European Union from earlier this year.

article thumbnail

CluePoints: 'there is true recognition risk-based quality management is not just monitoring'

Outsourcing Pharma

Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15 years, CluePoints says.

article thumbnail

Nanobiotix partners with Janssen to commercialise radioenhancer oncology drug

Pharmaceutical Technology

Janssen will have a worldwide licence to develop and commercialise Nanobiotix’s oncology drug, NBTXR3.

Drugs 130
article thumbnail

Samsung Biologics, after expanding Pfizer collab, inks Novartis production deal worth $391M

Fierce Pharma

Just days after sewing up a pair of $897 million deals with Pfizer, Samsung Biologics has added a few hundred million dollars more to its partnership cash pile—this time courtesy of an expanded pac | Samsung Biologics said in a Monday regulatory filing that it’s inked a $390.9 million deal to help crank out Novartis drugs. The latest production pact builds on an earlier tie-up worth $81 million.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

FDA approves label expansion for Novartis’ Leqvio

Pharmaceutical Technology

Leqvio has received approval for adjunct treatment in patients with elevated LDL cholesterol.

article thumbnail

Janssen reveals new Spravato data

Pharma Times

Period to remission was shortened with esketamine nasal spray in both sub-groups within study - News - PharmaTimes

110
110
article thumbnail

Novo Nordisk Sues Makers of Wegovy and Ozempic Dupes

XTalks

With the remarkable success of its semaglutide products Wegovy and Ozempic for weight loss and type 2 diabetes, respectively (the latter also for weight loss through off-label prescribing), Novo Nordisk is cracking down on pharmacies making compounded versions of the glucagon-like peptide-1 (GLP-1) receptor agonist drugs. In light of dupes making their way across pharmacies, the Danish company has launched a new round of lawsuits in the US against those that are making illegal versions of their

article thumbnail

GSK’s Arexvy authorised by MHRA

Pharma Times

Therapy is the first respiratory syncytial virus vaccine specifically developed for older adults - News - PharmaTimes

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pfizer invests $25 million in Caribou Biosciences

BioPharma Reporter

Pfizer has made a $25 million equity investment in leading clinical-stage biopharmaceutical company, Caribou Biosciences.

article thumbnail

BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs

BioSpace

After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.

article thumbnail

The Power of Rebranding: How Website Rebranding Drives Increased Traffic

Pharma Marketing Network

In today’s digital landscape, a website serves as a vital touchpoint for businesses to connect with their target audience. However, over time, a website can become outdated, lose relevance, or fail to resonate with visitors. When done strategically, rebranding a website can breathe new life into your online presence and significantly boost traffic.

article thumbnail

Novavax Amends COVID-19 Contract with Canada, Snags $350M for Unused Shots

BioSpace

The biotech will supply Canada with fewer doses of its coronavirus vaccine while reaching a financial agreement for the forfeiting of certain doses previously scheduled for delivery.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.